Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Empagliflozin”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04735042
What this trial is testing

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

Who this might be right for
Type 2 DiabetesUrinary Tract Infections
University of Pisa 60
Post-approval studies (Phase 4)Study completedNCT06171802
What this trial is testing

EMPagliflozin After Aortic Valve Replacement

Who this might be right for
Aortic Valve Stenosis
Rigshospitalet, Denmark 206
Post-approval studies (Phase 4)Study completedNCT04461041
What this trial is testing

Empagliflozin and Cardiac Remodelling in People Without Diabetes

Who this might be right for
Cardiovascular DiseasesLeft Ventricular Hypertrophy
Unity Health Toronto 169
Testing effectiveness (Phase 2)UnknownNCT04138251
What this trial is testing

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Who this might be right for
Glycogen Storage Disease Type IGlucose 6 Phosphatase Deficiency
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 5
Early research (Phase 1)Study completedNCT01844531
What this trial is testing

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Who this might be right for
Healthy
Boehringer Ingelheim 24
Early research (Phase 1)Study completedNCT05078879
What this trial is testing

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Who this might be right for
Crohn's DiseaseGlycogen MetabolismInflammatory Bowel Disease (IBD)
National Institute of Allergy and Infectious Diseases (NIAID) 4
Not applicableStudy completedNCT07556094
What this trial is testing

Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.

Who this might be right for
Obstructive Sleep Apnea (OSA)Sleep Apnea Syndrome, ObstructiveHeart Failure
Medical University of Bialystok 70
Not applicableStudy completedNCT07633041
What this trial is testing

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 1000 mg Tablets Under Fed Conditions.

Who this might be right for
Bioequivalence Study in Healthy Subjects
ADIUM 42
Very early researchUnknownNCT04203927
What this trial is testing

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Who this might be right for
Type2 DiabetesInsulin Sensitivity
University of Virginia 50
Post-approval studies (Phase 4)Looking for participantsNCT06613854
What this trial is testing

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus (T2DM)
University Medical Centre Ljubljana 90
Post-approval studies (Phase 4)UnknownNCT05140694
What this trial is testing

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Who this might be right for
Metabolic-associated Fatty Liver DiseaseType 2 Diabetes
Seoul National University Bundang Hospital 135
Post-approval studies (Phase 4)Study completedNCT02798744
What this trial is testing

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

Who this might be right for
Diabetes Mellitus, Type 2
University of Leicester 68
Large-scale testing (Phase 3)Study completedNCT01164501
What this trial is testing

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Who this might be right for
Diabetes Mellitus, Type 2Renal Insufficiency
Boehringer Ingelheim 741
Post-approval studies (Phase 4)Study completedNCT04143321
What this trial is testing

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

Who this might be right for
Diabetes Mellitus
Isfahan University of Medical Sciences 75
Testing effectiveness (Phase 2)Study completedNCT05757791
What this trial is testing

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Who this might be right for
Major Depressive Disorder
NYU Langone Health 20
Large-scale testing (Phase 3)Looking for participantsNCT06955260
What this trial is testing

SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

Who this might be right for
Congenital Heart Disease
Subodh Verma 410
Post-approval studies (Phase 4)Looking for participantsNCT06706791
What this trial is testing

Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II

Who this might be right for
Chronic Heart Failure
Fazaia Ruth Pfau Medical College 156
Large-scale testing (Phase 3)Study completedNCT05504226
What this trial is testing

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

Who this might be right for
Type 2 Diabetes
Handok Inc. 214
Large-scale testing (Phase 3)WithdrawnNCT06083675
What this trial is testing

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Novo Nordisk A/S
Large-scale testing (Phase 3)Study completedNCT01289990
What this trial is testing

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 2,705
Next Page